Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for RBGPF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for RBGPF and 80,000+ other tickers.
See exactly how RBGPF's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RBGPF and 80,000+ other tickers.
Reckitt Benckiser Group Plc engages in the manufacture and trade of consumer brand products including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, and Woolite. It operates through the following segments: Hygiene, Health, and Nutrition. The company was founded by Isaac Reckitt in 1840 and is headquartered in Slough, the United Kingdom.
Reckitt Benckiser Group LON: RKT reported 3.3% like-for-like net revenue growth in the third quarter, or 3.9% excluding Russia Hygiene, as strength in emerging markets and a return to growth in Europe were partly offset by supply constraints and a weaker consumer environment in North America.
In September Zegona announced a capital return program of €400 million, divided equally between dividends and share repurchases. McBride expects the agreement to increase annual revenues by £170 million at margins consistent with McBride's existing revenue base. Talen will borrow against its 2027 and 2028 guaranteed capacity payments, accelerating these payments and repurchasing $1.5 billion in shares by the end of March 2027.
A change in Reckitt's sales tactics led to 12 consecutive quarters of double-digit sales growth in the country.
These stocks have economic moats and look attractive today.
I rate Reckitt Benckiser a buy with a 12–24 month horizon and medium confidence, citing a 21% discount to peer multiples despite litigation overhang. Core Reckitt delivers high-margin, volume-led growth, with FY2025 organic growth of +5.2% and a 26.7% adjusted operating margin, supporting quality business status. Mead Johnson litigation risk remains the key discount driver; recent favorable legal outcomes improve sentiment but do not resolve federal MDL exposure.